Skip to main content

Table 1 Baseline Features of the Included Cases (n = 75) – all underwent mpMRI and 68 Ga-PSMA-11 PET/CT and Radical Prostatectomy

From: Prediction of T staging in PI-RADS 4–5 prostate cancer by combination of multiparametric MRI and 68Ga-PSMA-11 PET/CT

Characteristics

Value

Age (years), median (range)

69 (55–84)

Initial PSA (ng/dL), median (range)

14.20 (4.15–120.00)

aGleason score, n (%)

 3 + 3 = 6

4 (5.3)

 3 + 4 = 7

27 (36.0)

 4 + 3 = 7

22 (29.3)

 8 point

11 (14.7)

 9–10 point

11 (14.7)

pT stage, n (%)

 2

27 (36.0)

 3

48 (64.0)

aPI-RADS, n (%)

 3

29 (38.7)

 4–5

46 (61.3)

aMI-ES, n (%)

 1

7 (9.3)

 2

35 (46.7)

 3

33 (44.0)

aADCmean (μm2 /s), median (range)

725 (444–1155)

aSUVmax, median (range)

14.23 (5.54–90.34)

Percentage of positive core at TB (%), median(range)

36 (7–100)

ISUP Gleason score at TB, n (%)

 1

13 (17.3)

 2

14 (18.7)

 3

9 (12.0)

 4

27 (36.0)

 5

12 (16.0)

  1. mpMRI multiparametric magnetic resonance imaging, PET/CT positron emission tomography computed tomography, PSA prostate-specific antigen, ISUP International Society of Urological Pathology, TB targeted biopsy, PI-RADS Prostate Imaging Reporting and Data System, MI-ES a miPSMA expression score, ADCmean average apparent diffusion coefficient, SUVmax maximum standardized uptake value
  2. aFor patients with multifoci, the data are based on index lesions